However, treatment of LNWT with high dose lorvotuzumab-mertansine resulted in reduction of tumour size followed by a plateau suggesting that once all NCAM+ cells were eliminated, the remaining NCAM− cells comprising most of these xenografts lacked CIC capacity. This evidence concerns the gene NCAM1 and neoplasm.